Please join us for our next free, public lecture, A Focus on Parkinson’s, Alzheimer’s and Lewy Body Dementia, on Tuesday, May 7. This informative event will feature presentations and a Q&A session with VAI scientists working at the intersection of these three diseases.
In the next decade, the prevalence of neurodegenerative diseases is expected to rise dramatically. Today, 5 million people in the U.S. are living with Alzheimer’s, and by 2060 this number is projected to climb to nearly 14 million. Parkinson’s is also on the rise; by 2020 there will be nearly 1.2 million people living with the disease in the U.S. Although lesser known, Lewy body dementia is the second most common type of progressive dementia after Alzheimer’s disease, and while it is underreported and often misdiagnosed, approximately 1.3 million people in the U.S. are affected by this disease.
While these statistics are alarming, there is hope on the horizon. VAI scientists, along with national and international collaborators, are making significant strides toward the development of new diagnostics and therapies that slow or stop disease progression – something no current treatment can accomplish.
If you’re interested in hearing directly from scientists working on the front lines of groundbreaking research, and learning more about these complex neurodegenerative diseases, be sure to register for A Focus on Parkinson’s, Alzheimer’s and Lewy Body Dementia today.
Registration includes a complimentary boxed lunch and refreshments during the event.
Complimentary valet parking will be available.
Dr. José Brás is a leading molecular geneticist whose research focuses on how genetic variability impacts the onset and progression of neurodegenerative diseases such as Parkinson’s and Alzheimer’s. He earned his B.Sc. in biomedical sciences from Coimbra Polytechnic Institute, followed by his M.S. in biomolecular methods from Aveiro University, and his Ph.D. (with honors) from Coimbra University. He conducted his doctoral research under the supervision of Dr. Andrew Singleton and Dr. Catarina Oliveira at the Laboratory of Neurogenetics at the National Institute on Aging of the National Institutes of Health, where he investigated the genetic basis of movement disorders. In 2010, he joined University College London as a postdoctoral research assistant in the Department of Molecular Neuroscience. In 2015, he became a tenured principal investigator and was later named as a program leader at the UK Dementia Research Institute at UCL. In 2018, Dr. Brás joined the Institute’s Center for Neurodegenerative Science as an associate professor.
He has received several awards and honors, including the 2014 Alzheimer’s Society Research Fellowship and the 2016 Alzheimer’s Society Dementia Research Leader Award.
He serves as an ad hoc reviewer for several journals, including Neurobiology of Aging, Annals of Neurology, Current Genomics, Neuron, American Journal of Human Genetics and Brain. He is a member of the editorial board of the Journal of Parkinson’s Disease (and Brain Communications) and an associate editor for Frontiers in Neurology — Neurogenetics.
Dr. Rita Guerreiro is a leader in parsing the genetic variations that contribute to neurodegenerative diseases such as Parkinson’s and Alzheimer’s diseases. She earned her B.Sc. in biomedical sciences from Coimbra Health Technology Institute, her M.S. degree in biomolecular methods from Aveiro University and her Ph.D. (with honors) from Coimbra University, all in Portugal. Her pre-doctoral work was supervised by Dr. John Hardy and Dr. Catarina Oliveira, and was conducted at the Laboratory of Neurogenetics at the National Institute on Aging, National Institutes of Health. While there, she studied the genetics of dementia, with a focus on searching for new mutations and new genes underlying Alzheimer’s disease and frontotemporal dementia. In 2010, she joined the Department of Molecular Neuroscience at University College London’s Institute of Neurology as a postdoctoral research fellow, where she explored genetic variability in several neurological diseases (mainly Parkinson’s and Alzheimer’s diseases) and investigated how genetic variants affect the disease process at the molecular level. In 2015, she became a principal investigator in the Department of Molecular Neuroscience, after holding a Travelling Research Fellowship US from Alzheimer’s Research UK (2012–2015) and obtaining a Senior Research Fellowship from Alzheimer’s Society (2015–2019). In 2017 she was named program leader at the UK Dementia Research Institute at University College London. In 2018, she the Institute’s Center for Neurodegenerative Science as an associate professor.
Dr. Guerreiro was the first recipient of the Alzheimer’s Research UK Young Investigator of the Year Award in 2016, and also earned the 2015 Fondazione Gino Galletti Neuroscience Prize and the 2015 Alzheimer’s Society Dementia Research Leaders Award. She was recognized as a Personality of the Year in 2015 by Dr. Anibal Cavaco Silva, president of the Portuguese Republic. In 2014, Dr. Guerreiro received the IFRAD (Fondation pour la Recherche sur Alzheimer) European Grand Prix for Young Researchers.
She serves on the editorial boards of the American Journal of Neurodegenerative Disease, Science Matters, Journal of Alzheimer’s Disease and Journal of Parkinson’s Disease, and is an advisory editor for Neurobiology of Aging.